Scopio’s partnership with Siemens Healthineers will “accelerate digital workflow transformation in hematology laboratories worldwide,” Scopio CEO Itai Hayut said. [Photo courtesy of Siemens Healthineers]
Scopio and Siemens Healthineers today announced a global distribution deal for the Scopio X100 and Scopio X100HT.
Siemens said those full-field digital cell morphology technology systems will complement its own Atellica HEMA 570 and Atellica HEMA 580 analyzers to give labs “high-resolution, full-field viewing for peripheral blood specimens and artificial intelligence-based morphological analysis with remote capabilities through the secure hospital network.”
Siemens Healthineers Head of Diagnostics Sharon Bracken called the deal “a step forward in delivering automated and digitized solutions that would redefine hematology workflow.”
“By offering laboratorians access to novel digital hematology technologies in one of the lab’s busiest testing disciplines, we will be providing critical tools to optimize operational workflow and laboratory efficiency, accelerate diagnosis, and improve patient care while addressing reduced resource capacity,” she said in a news release.
Siemens Healthineers is one of the biggest allies a medtech developer could ask for. It’s the third-largest medical device company in the world, according to our 2022 Medtech Big 100 ranking by revenue.
But it’s not the first major partnership for Scopio, which teamed up with Beckman Coulter last year after securing its latest FDA clearance.
“With Siemens Healthineers’ strong focus on data-driven clinical decision-making and our shared mission to innovate and shape the future of hematology, we are excited to include our Full-Field Cell Morphology imaging and analysis platforms as a part of their extensive laboratory diagnostics portfolio.” Scopio Labs co-founder and CEO Itai Hayut said in a news release. “This partnership will help accelerate digital workflow transformation in hematology laboratories worldwide to enhance clinical decisions for optimal patient care.”
How Scopio’s telehematology technology works
The Scopio systems examine blood cell samples digitally, which allows for remote analysis with AI-powered decision support for faster results.
When a lab runs a patient sample on a hematology analyzer and finds abnormalities or need for analysis, the Scopio imaging platform can digitize a blood smear. The AI-powered system scans the sample and locates, annotates and presents images of blood cells at 100X resolution, flagging anomalies and suggesting classifications for review and confirmation.
Once it’s digitized, the sample can be viewed for analysis by hematopathologists and other lab professionals remotely, not just by whoever’s near enough to peer into a microscope.
Scopio’s technology can also automate slide preparation, loading and processing.
Scopio said the Full-Field Peripheral Blood Smear Application, for example, can reduce peripheral blood smear review turnaround time by 60 percent.
That application is FDA-cleared and has a CE mark for the Scopio X100 and X100HT. Scopio also has a CE mark for its Full-Field Bone Marrow Aspirate Application on both devices.
